Latest Geron Corporation Stories
Provides for Immediate Release of Initial Grant Funds MENLO PARK, Calif., Oct. 20, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
President-Elect of the Society for Cryobiology and Former Cell Therapy Executive Join Leading Clinicians, Developers, and Consultants in the Biobanking, Drug Discovery, and Regenerative Medicine Markets BOTHELL,
-Conference Call and Webcast on September 12, 2014 at 8:30 a.m. ET, 5:30 a.m. PT- MENLO PARK, Calif. and LONDON, Sept.
MENLO PARK, Calif., Sept. 4, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
Dose Escalation Clinical Trial to Test Initial Safety and Activity of AST-OPC1 in Patient Population with the First Indication Targeted for Product Registration MENLO PARK, Calif.,
- Welcomes New Shareholders Who Received Series A Shares from Geron Corporation - MENLO PARK, Calif., Aug. 21, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
- Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT - MENLO PARK, Calif., July 24, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
SAN DIEGO, May 29, 2014 /PRNewswire/ -- ViaCyte, Inc., a regenerative medicine company focused on developing a cell replacement therapy for the treatment of patients with insulin-dependent diabetes,
Transparency Market Research Report added "Human Embryonic Stem Cells Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database.
NEW YORK, April 7, 2014 /PRNewswire/ -- Geron Corporation (NasdaqGS: GERN), an emerging competitor, is developing a telomerase inhibitor called Imetelstat in hematologic myeloid malignancies.
- An imitative word; an onomatopoetic word.